In vitro fibrillogenesis of the amyloid β1-42 peptide: Cholesterol potentiation and aspirin inhibition

Micron

Volumn 33, Issue 7-8, 2002, Pages 609-626

  Harris, J R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Amyloid 1 42 peptide; Aspirin; Cholesterol; Copper; Fibrillogenesis; Helical fibril filament; Negative staining; Polymerization; Protofibril; Sphingomyelin; Transmission electron microscopy

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CHOLESTEROL; COPPER; PEPTIDE; SPHINGOMYELIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; CHEMISTRY; DIMERIZATION; ELECTRON MICROSCOPY; HUMAN; PATHOPHYSIOLOGY; RAT; SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ASPIRIN; CHOLESTEROL; COPPER; DIMERIZATION; HUMANS; MICROSCOPY, ELECTRON; PEPTIDES; RATS; SPHINGOMYELINS;

ANIMALIA;

EID: 0036444474     PISSN: 09684328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-4328(02)00029-X     Document Type: Article

References (98)

1. Atwood, C.S., Moir, R.D., Huang, X., Scarpa, R.C., Bacarra, M.E., Romano, D.A., Hartshorn, M.A., Tanzi, R.E., Bush, A.I., 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12817-12826.
2. Avdulov, N.A., Chochina, S.V., Igbavboa, U., Warden, C.S., Vassiliev, A.V., Wood, W.G., 1997. Lipid binding to amyloid β-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 1746-1752.
3. Barrow, C.J., 2002. Advances in the development of A beta-related therapeutic strategies for Alzheimer's disease. Drug News Perspect. 15, 102-109.
4. Behl, C., 1999. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches. Prog. Neurobiol. 57, 301-323.
5. Bohrmann, B., Adrian, M., Dubochet, J., Kuner, P., Muller, F., Huber, W., Nordstedt, C., Döbeli, H., 2000. Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130, 232-246.
6. Brenner, S., Horne, R.W., 1959. A negative staining method for high resolution electron microscopy of viruses. Biochim. Biophys. Acta 34, 60-71.
7. Campbell, A., 2002. The potential role of aluminium in Alzheimer's disease. Nephrol. Dial. Transplant. 17 (Suppl. 2), 17-20.
8. Cardoso, I., Goldsbury, C.S., Muller, S.A., Olivier, V., Wirtz, S., Damas, A.M., Aebi, U., Saraiva, M.J., 2002. Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled transthyretin amyloid-like fibrils. J. Mol. Biol. 317, 683-695.
9. Chaney, M.O., Webster, S.D., Kuo, Y.M., Roher, A.E., 1998. Molecular modelling of the A beta 1-42 peptide from Alzheimer's disease. Protein Engng 112, 761-767.
10. Cherny, R.A., Legg, J.T., McLean, C.A., Fairlie, D.P., Huang, X., Atwood, C.S., Beyreuther, K., Tanzi, R.E., Masters, C.L., Bush, A.I., 1999. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 272, 23223-23228.
11. 1-40 increases neuronal membrane fluidity: Role of cholesterol and brain region. J. Lipid Res. 42, 1292-1297.
12. Choo-Smith, L.-P., Garzon-Rodriguez, W., Glabe, C.G., Surewicz, W.K., 1997. Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272, 22987-22990.
13. Cuajungco, M.P., Goldstein, L.E., Nunomura, A., Smith, M.A., Lim, J.T., Atwood, C.S., Huang, X., Farrag, Y.W., Perry, G., Bush, A.I., 2000. Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem. 275, 19439-19442.
14. 1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc. Natl Acad. Sci. USA 92, 2313-2317.
15. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., Hartmann, T., 2001. Simvastin strongly reduced levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861.
16. Findeis, M.A., 2000. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim. Biophys. Acta 1502, 76-84.
17. Golde, T.E., Eckman, C.B., 2001. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov. Today 6, 1049-1055.
18. Goldsbury, C., Kistler, J., Aebi, U., Arvinte, T., Cooper, J.S., 1999. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J. Mol. Biol. 285, 33-39.
19. Goldsbury, C.S., Wirtz, S., Müller, S.A., Sunderji, S., Wicki, P., Aebi, U., Frey, P., 2000. Studies on the in vitro assembly of Aβ1-40: implications for the search for Aβ fibril formation inhibitors. J. Struct. Biol. 130, 217-231.
20. Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T., 1997a. Observation of metastable A beta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125.
21. Harper, J.D., Lieber, C.M., Lansbury, P.T., 1997b. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzhemier's disease amyloid-beta protein. Chem. Biol. 4, 951-959.
22. Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T., 1999. Assembly of Aβ amyloid fibrils: An in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 8972-8980.
23. Harris, J.R., 1988. Electron microscopy of cholesterol. Micron Microsc. Acta 19, 19-32.
24. Harris, J.R., 1997. Negative Staining and Cryoelectron Microscopy, RMS Microscopy Handbook No. 35, Bios Scientific Publishers, Oxford, UK.
25. Harris, J.R., Agutter, P.S., 1970. A negative staining study of human erythrocyte ghosts and rat liver nuclear membranes. J. Ultrastruct. Res. 33, 219-232.
26. Harris, J.R., Horne, R.W., 1991. Negative staining. In: Harris, J.R., (Ed.), Electron Microscopy in Biology: A Practical Approach, Practical Approach Series, IRL/OUP, Oxford, pp. 203-228.
27. Harris, J.R., Scheffler, D., 2002. Routine preparation of air-dried negatively stained and unstained specimens on holey carbon support films: A review of applications. Micron 33, 461-480.
28. Hartmann, T., 2001. Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci. 24 (Suppl. 11), S45-S48.
29. Herrmann, H., Aebi, U., 1999. Intermediate filament assembly: Temperature sensitivity and polymorphism. Cell. Mol. Life Sci. 55, 1416-1431.
30. Huang, T.H.J., Yang, D.-S., Plaskos, N.P., Go, S., Yip, C.M., Fraser, P.E., Chakrabartty, A., 2000. Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide. J. Mol. Biol. 297, 73-87.
31. Jansson, E.T., 2001. Aluminium exposure and Alzheimer's disease. J. Alzheimer's Dis. 3, 541-549.
32. Ji, Y., Permanne, B., Sigurdsson, E.M., Holzman, D.M., Wisniewski, T., 2001. Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimer's Dis. 3, 23-30.
33. Jiménez, J.L., Guijarro, J.I., Orlova, E., Zurdo, J., Dobson, C.M., Sunde, M., Saibil, H.R., 1999. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18, 815-821.
34. Jiménez, J.L., Tennent, G., Pepys, M., Saibil, H.R., 2001. Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. J. Mol. Biol. 311, 241-247.
35. Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., 2001. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276, 24985-24990.
36. Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., 2002. Interactions of the amyloid β-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41, 7385-7390.
37. Kalmijn, S., Launer, L.J., Ott, A., Witteman, J.C., Hofman, A., Bretles, M.M., 1997. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann. Neurol. 42, 776-782.
38. Kirkitadze, M.D., Condron, M.M., Teplow, D.B., 2001. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312, 1103-1119.
39. Kiuchi, Y., Isobe, Y., Fukushima, K., 2002. Type IV collagen prevents amyloid β-protein fibril formation. Life Sci. 70, 1555-1564.
40. Kojro, E., Gimpl, G., Lammisch, S., März, W., Farenholz, F., 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 5815-5820.
41. Kontush, A., 2001. Amyloid-β an anti-oxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. Biol. Med. 9, 1120-1131.
42. Kowalewski, T., Holtzman, D.M., 1999. In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation. Proc. Natl Acad. Sci. USA 96, 3688-3693.
43. Kuo, Y.M., Emmerling, M.R., Bisgaier, C.L., Essenburg, A.D., Lampert, H.C., Drumm, D., Roher, A.E., 1998. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A beta 1-42 levels. Biochem. Biophys. Res. Commun. 252, 711-715.
44. Lashuel, H.A., LaBrenz, S.R., Woo, L., Serpell, L.C., Kelly, J.W., 2000. Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly: Implications for amyloid fibril formation and materials science. J. Am. Chem. Soc. 122, 5262-5277.
45. Li, L., Darden, T.A., Bartolotti, L., Kominos, D., Pederson, L.G., 1999. An atomic model for the pleated β-sheet structure of Aβ amyloid protofilaments. Biophys. J. 76, 2871-2878.
46. Lim, G.P., Yang, F., Chu, T., Gahtan, E., Ubeda, O., Beech, W., Overmier, J.B., Hsiao-Ashec, K., Frautschy, S.A., Cole, G.M., 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983-991.
47. Liu, S.-T., Howlett, G., Barrow, C.J., 1999. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer's disease. Biochemistry 38, 9373-9378.
48. Lo Nostro, P., Capuzzi, G., Romani, A., Mulinacci, N., 2000. Self-assembly and anti-oxidant properties of octanoyl-6-O-ascorbic acid. Langmuir 16, 1744-1750.
49. Lorenzo, A., Yankner, B.A., 1994. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12243-12247.
50. Lynch, T., Cherny, R.A., Bush, A.I., 2000. Oxidative processes in Alzheimer's disease: The role of the Aβ-metal interactions. Exp. Gerontol. 35, 445-451.
51. Mahfoud, R., Garmy, N., Maresca, M., Yahi, N., Puigserver, A., Fantini, J., 2002. Identification of a common sphingolipid-binding domain in Alzheimer, prion and HIV-1 proteins. J. Biol. Chem. 277, 11292-11296.
52. Mackenzie, I.R.A., 2001. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol. Aging 22, 819-822.
53. Malinchik, S.B., Inouye, H., Szumowski, K.E., Kirschner, D.A., 1998. Structural analysis of Alzheimer's β (1-40) amyloid: Protofilament assembly of tubular fibrils. Biophys. J. 74, 537-545.
54. Mason, R.P., Shoemaker, W.J., Shajenko, L., Chambers, T.E., Herbbette, L.G., 1992. Evidence for changes in the Alzeimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13, 413-419.
55. McLaurin, J., Yang, D.-S., Yip, C.M., Fraser, P.E., 2000. Modulating factors in amyloid-β fibril formation. J. Struct. Biol. 130, 259-270.
56. Miranda, S., Opazo, C., Larrondo, L.F., Muñoz, F.J., Ruiz, F., Leighton, F., Inestrosa, N.C., 2000. The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog. Neurobiol. 62, 633-648.
57. Miura, T., Suzuki, K., Kohata, N., Takeuchi, H., 2000. Metal binding modes of Alzheimer's amyloid β-peptide in insoluble aggregates and soluble complexes. Biochemistry 39, 7024-7031.
58. Mizuno, T., Nakata, M., Naiki, H., Michikawa, M., Wang, R., Haass, C., Yanagisawa, K., 1999. Cholesterol-dependent generation of a seeding amyloid β-protein in cell culture. J. Biol. Chem. 274, 15110-15114.
59. Moir, R.D., Atwood, C.S., Romano, D.M., Laurans, M.H., Huang, X., Bush, A.I., Smith, J.D., Tanzi, R.E., 1999. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations. Biochemistry 38, 4595-4603.
60. Mothes, E., Shoeman, R.L., Schröder, R.R., Traub, P., 1990. Polymerizing properties of pepstatin A. J. Struct. Biol. 105, 80-91.
61. Nguyen, K.V., Gendrault, J.L., Wolff, C.M., 2002. Poly-L-lysine dissolves fibrillar aggregation of the Alzheimer beta-amyloid peptide in vitro. Biochem. Biophys. Res. Commun. 291, 764-768.
62. Nichols, M.R., Moss, M.A., Reed, D.K., Lin, W.-L., Mukhopadhyay, R., Hoh, J.H., Rosenberry, T.L., 2002. Growth of β-amyloid (1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 41, 6115-6127.
63. Notkola, I.L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., Nissinen, A., 1998. Serum cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17, 14-20.
64. 1-42 fibrillogenesis. Scand. J. Immunol. 49, 219-223.
65. Okamura, N., Arai, H., Maruyama, M., Matsui, T., Tanji, H., Sasaki, H., Yoshida, H., Sugita, M., 2001. Serum cholesterol and cerebrospinal fluid amyloid β protein in Alzheimer's disease. J. Am. Geriatr. Soc. 49, 1738-1739.
66. Oyewole, D., Mann, D.M.A., Royston, M.C., 1999. Apolipoprotein E epsilon 4 genotype and the morphology of amyloid plaques in Alzheimer's disease. Alzheimer's Rep. 2, 267-270.
67. Parvathy, S., Davies, P., Haroutunian, V., Purohit, D.P., Davis, K.L., Mohs, R.C., Park, H., Moran, T.M., Chan, J.Y., Buxbaum, J.D., 2001. Correlation between the Aβx-, 40-Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch. Neurobiol. 58, 2025-2032.
68. Perutz, M.F., Finch, J.T., Lesk, A., 2002. Amyloid fibers are water-filled nanotubes. Proc. Natl Acad. Sci. USA 99, 5591-5595.
69. Refolo, L.M., Pappolla, M.A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G.S., Sambamurti, K., Duff, K., 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331.
70. 1-42. J. Neurosci. Res. 66, 573-582.
71. Roher, A.E., Baudry, J., Chaney, M.O., Kuo, Y.-M., Stine, W., Emmerling, M.R., 2000. Oligomerization and fibril assembly of the amyloid-β protein. Biochim. Biophys. Acta 1502, 31-43.
72. Rosenblum, W.I., 2002. Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: New findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis. Neurobiol. Aging 23, 225-230.
73. Selkoe, D.J., 2001. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimer's Dis. 3, 75-80.
74. Serpell, Li. C., 2000. Alzheimer's amyloid fibrils: Structure and assembly. Biochim. Biophys. Acta 1502, 16-30.
75. Shivji, A.P., Brown, F., Davies, M.C., Jennings, K.H., Roberts, J.C., Tendler, S.J.B., Wilkinson, M.J., Williams, P.M., 1995. Scanning tunnelling microscopy studies of β-amyloid fibril structure and assembly. FEBS Lett. 371, 25-28.
76. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C.G., Simons, K., 1998. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460-6464.
77. Simons, M., Keller, P., Dichgans, J., Schulz, J.B., 2001. Cholesterol and Alzheimer's disease. Neurology 57, 1089-1093.
78. Smith, M.A., Rottkamp, C.A., Nunomura, A., Raina, A.K., Perry, G., 2000. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502, 139-144.
79. Snyder, S.W., Ladror, U.S., Wade, W.S., Barrett, L.W., Matayoshi, E.D., Huffaker, H.J., Krafft, G.A., Holzman, T.F., 1994. Amyloid-beta aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 1216-1228.
80. Soto, C., 1999. Plaque busters: Strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today 5, 343-350.
81. Soto, C., Saborio, G.P., Permanne, B., 2000. Inhibiting the conversion of soluble amyloid-β peptide into abnormally folded amylogenic intermediates: Relevance for Alzheimer's disease therapy. Acta Neurol. Scand. 176, 90-95.
82. Stanyer, L., Betteridge, D.J., Smith, C.C.T., 2002. An investigation into the mechanisms mediating plasma lipoprotein-potentiated β-amylogenesis. FEBS Lett. 518, 72-78.
83. Teplow, D.B., 1998. Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid: Int. J. Exp. Clin. Invest. 5, 121-142.
84. Thomas, T., Nadachal, T.G., Thomas, K., 2001. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12, 3263-3267.
85. Tjernberg, L.O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A.R., Thyberg, J., Terenius, L., Nordstedt, C., 1996. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548.
86. Tomiyama, T., Shoji, A., Katoaka, K., Suwa, Y., Asano, S., Kaneko, H., Endo, N., 1996. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J. Biol. Chem. 271, 6839-6844.
87. Ueda, T., Nagata, M., Monji, A., Yoshida, I., Tashiro, N., Imoto, T., 2002. Effect of sucrose on formation of the β-amyloid fibrils and D-aspartic acids in Aβ1-42. Biol. Pharm. Bull. 25, 375-378.
88. Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D.A., 2000. Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208.
89. Velez-Pardo, C., Del Rio, M.J., Lopera, F., 1998. Familial Alzheimer's disease: Oxidative stress, β-amyloid, presenilins, and cell death. Gen. Pharmacol. 31, 675-681.
90. Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M., Teplow, D.B., 1997. Amyloid β-protein fibrillogenesis. J. Biol. Chem. 272, 22364-22372.
91. Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J., Teplow, D.B., 1999. Amyloid β-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952.
92. Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E., Koo, E.H., 2001. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
93. Wegiel, J., Bobinski, M., Tarnawski, M., Dziewiatkowski, J., Popovitch, E., Dobinski, M., Lach, B., Reisberg, B., Miller, D.C., de Santi, S., de Leon, M.J., 2001. Shiftfrom fibrillar to non-fibrillar Aβ deposits in the neocortex of subjects with Alzheimer disease. J. Alzheimer's Dis. 3, 49-57.
94. Wood, S.J., MacKenzie, L., Maleeff, B., Hurle, R.M., Wetzel, R., 1996. Selective inhibition of A beta fibril formation. J. Biol. Chem. 271, 4086-4092.
95. Yamazaki, T., Chang, T.-Y., Haass, C., Ihara, Y., 2001. Accumulation and aggregation of amyloid β-protein in late endosomes of Niemann-Pick type C cells. J. Biol. Chem. 276, 4454-4460.
96. Yankner, B.A., 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.
97. Yip, C.M., McLaurin, J., 2001. Amyloid-β peptide assembly: A critical step in fibrillogenesis and membrane disruption. Biophys. J. 80, 1359-1371.
98. Zagorski, M.G., Yang, J., Shao, H., Ma, K., Zerng, H., Honh, A., 1999. Methodological and chemical factors affecting amyloid β-peptide amyloidogenicity. Meth. Enzymol. 309, 189-204.